Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer

Thyroid

Volumn 20, Issue 2, 2010, Pages 135-146

  Biondi, Bernadette ^a   Cooper, David S ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTROGEN; LEVOTHYROXINE; THYROTROPIN; VITAMIN D;

AGING; BONE DENSITY; CANCER MORTALITY; CANCER RECURRENCE; COMORBIDITY; DIFFERENTIATED THYROID CANCER; FRACTURE; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE MASS; HEART RATE; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HUMAN; HYPERTHYROIDISM; LONG TERM CARE; METASTASIS; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK FACTOR; RISK MANAGEMENT; THYROID CANCER; THYROTROPIN BLOOD LEVEL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; BONE DENSITY; FEMALE; HEART; HEART RATE; HUMANS; HYPERTHYROIDISM; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; RISK; RISK FACTORS; THYROID NEOPLASMS; THYROTROPIN; THYROXINE;

EID: 77149121414     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2009.0311     Document Type: Review

References (118)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ 2008 Cancer Statistics. CA Cancer J Clin 58:71-96.
2. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
3. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W and the European Thyroid Cancer Taskforce 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 54:787-803.
4. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295: 2164-2167.
5. Liu S, Semenciw R, Ugnat AM, Mao Y 2001 Increasing thyroid cancer incidence in Canada, 1970-1996: time trends and age-period-cohort effects. Br J Cancer 85:1335-1339.
6. Leenhardt L, Grosclaude P, Chérié-Challine L 2004 Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 12:1056-1060.
7. dos Santos Silva I, Swerdlow AJ 1993 Thyroid cancer epidemiology in England and Wales: time trends and geographical distribution. Br J Cancer 67:330-340.
8. Mihailescu DV, Schneider AB 2008 Size, number and distribution of thyroid nodules and their risk of malignancy in radiation-exposed patients who underwent surgery. J Clin Endocrinol Metab 93:2188-2193.
9. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB, Goellner JR, Hay ID, Hertzberg BS, Intenzo CM, Jeffrey RB, Langer JE, Larsen PR, Mandel SJ, Middleton WD, Reading CC, Sherman SI, Tessler FN 2005 Society of Radiologists in Ultrasound. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 237:794-800.
10. Morris LF, Ragavendra N, Yeh MW 2008 Evidence-based assessment of the role of ultrasonography in the management of benign thyroid nodules. World J Surg 32:1253-1263.
11. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R 2008 BRAF (V600E) mutation and the biology of papillary thyroid cancer. Endocr- Relat Cancer 15:191-205.
12. Pettersson B, Coleman MP, Ron E, Adami HO 1996 Iodine supplementation in Sweden and regional trends in thyroid cancer incidence by histopathologic type. Int J Cancer 65:13-19.
13. Chen AY, Jemal A, Ward EM 2009 Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 115:3801-3807.
14. Rego-Iraeta A, Pérez-Méndez LF, Mantinan B, Garcia- Mayor RV 2009 Time trends for thyroid cancer in northwestern Spain: true rise in the incidence of micro and larger forms of papillary thyroid carcinoma. Thyroid 19:333-340.
15. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, Devesa SS 2009 Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 18:784-791.
16. Biondi B, Filetti S, Schlumberger M 2005 Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 1:32-40.
17. Sundram F, Robinson BG, Kung A, Lim-Abrahan MA, Bay NQ, Chuan LK, Chung JH, Huang SM, Hsu LC, Kamaruddin N, Cheah WK, Kim WB, Koong SS, Lin HD, Mangklabruks A, Paz-Pacheco E, Rauff A, Ladenson PW 2006 Well-differentiated epithelial thyroid cancer management in the Asia Pacific region: a report and clinical practice guideline. Thyroid 16:461-469.
18. Pitoia F, Ward L, Wohllk N, Friguglietti, C, Tomimori E, Gauna, A, Camargo R, Vaisman M, Harach R, Munizaga F, Corigliano S, Pretell E, Niepomniszcze H 2009 Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metab 53:884-897
19. Pötter E, Horn R, Scheumann GF, Dralle H, Costagliola S, Ludgate M, Vassart G, Dumont JE, Brabant G 1994 Western blot analysis of thyrotropin receptor expression in human thyroid tumors and correlation with TSH-binding. Biochem Biophys Res Commun 205:361-367.
20. Lacroix L, Pourcher T, Magnon C, Bellon N, Talbot M, Intaraphairot T, Caillou B, Schlumberger M, Bidart JM 2004 Expression of the apical iodide transporter in human thyroid tissues: a comparison study with other iodide transporters. J Clin Endocrinol Metab 89:1423-1428.
21. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D 2007 BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism J Clin Endocrinol Metab 92:2840-2843.
22. Brabant G 2008 Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets? J Clin Endocrinol Metab 93:1167-1169.
23. Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT 1999 Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid 9:435-441.
24. Pacini F, Lari R, Mazzeo S, Grasso L, Taddei D, Pinchera A 1985 Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol (Oxf ) 23:405-411.
25. Heemstra KA, Liu YY, Stokkel M, Kievit J, Corssmit E, Pereira AM, Romijn JA, Smit JW 2007 Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol (Oxf ) 66:58-64.
26. Dulgeroff AJ, Hershman JM 1994 Medical therapy for differentiated thyroid carcinoma. Endocr Rev 15:500-515.
27. Ichikawa Y, Saito E, Abe Y, Homma M, Muraki T 1976 Presence of TSH receptor in thyroid neoplasms. J Clin Endocrinol Metab 42:395-398.
28. Carayon P, Thomas-Morvan C, Castanas E, Tubiana M 1980 Human thyroid cancer: membrane thyrotropin binding and adenylate cyclase activity J Clin Endocrinol Metab 51:915-920.
29. Balme HW 1954 Metastatic carcinoma of the thyroid successfully treated with thyroxine. Lancet 266:812-813.
30. Crile G Jr. 1966 Endocrine dependency of papillary carcinomas of the thyroid. JAMA 195:721-724.
31. Wang PW, Wang ST, Liu RT, Chien WY, Tung SC, Lu YC, Chen HY, Lee CH 1999 Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 84:4549-4553.
32. Sfakianakis GN, Skillman TG, George JM 1975 Thyroxine withdrawal in thyroid cancer. Ohio State Med J 71:79-82.
33. Goldberg LD, Ditchek NT 1981 Thyroid carcinoma with spinal cord compression. JAMA 245:953-954.
34. Burmeister LA, Goumaz MO, Mariash CN, Oppenheimer JH 1992 Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 75:344-350.
35. Kamel N, GüllüS, Dagcilgin S, Corapçioglu D, Tonyukuk Cesur V, Uysal AR, Başkal N, Erdogan G 1999 Degree of thyrotropin suppression in differentiated thyroid cancer without recurrence or metastases. Thyroid 9:1245-1248.
36. Mazzaferri EL, Massoll L 2002 Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr-Relat Cancer 9:227-247.
37. Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM, Stewart AK, Hölzer S 2000 Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 89:202-217.
38. Biondi B, Cooper DS 2008 The clinical significance of subclinical thyroid disease. Endocr Rev 29:76-131.
39. Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G 2005 Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol 152:1-9.
40. British Thyroid Association and Royal College of Physicians 2007 Guidelines for management of thyroid cancer. Available at www.btf-thyroid.org. Accessed December 1, 2007.
41. American Association of Clinical Endocrinologists, American College of Endocrinology 2001 Thyroid Carcinoma Taskforce AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. Endocr Pract 7:202-220.
42. Kendall-Taylor P; Guidelines Working Group 2003. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf ) 58:400-402.
43. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428.
44. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C 1996 Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 81:4318-4323.
45. Cady B, Cohn K, Rossi RL, Sedgwick CE, Meissner WA, Werber J, Gelman RS 1983 The effect of thyroid hormone administration upon survival in patients with differentiated thyroid carcinoma. Surgery 94:978-983.
46. McGriff NJ, Csako G, Gourgiotis L, Lori CG, Pucino F, Sarlis NJ 2002 Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 34:554-564.
47. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierly JD, Haugen BR, Klein I, Robbins J, Sherman SI, Taylor T, Maxon HR III 1998 Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8:737-744.
48. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI 2006 Outcomes of patients with differentiated thyroid carcinoma following initial therapy Thyroid 16:1229-1242.
49. Hovens GC, Stokkel MP, Kievit J, Corssmit EP, Pereira AM, Romijn JA, Smit JW 2007 Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab 92:2610-2615. (Pubitemid 47037365)
50. Botella-Carretero JI, Galan JM, Caballero C, Sancho J, Escobar-Morreale HF 2003 Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. Endocr-Relat Cancer 10:601-610.
51. Biondi B, Fazio S, Carella C, Sabatini D, Amato G, Cittadini A, Bellastella A, Lombardi G, Saccà L 1994 Control of adrenergic overactivity by b-blockade improves quality of life in patients receiving long term suppressive therapy with levothyroxine. J Clin Endocrinol Metab 78:1028-1033.
52. Biondi B, Fazio S, Cuocolo A, Sabatini D, Nicolai E, Lombardi G, Salvatore M, Saccà L 1996 Impaired cardiac reserve and exercise capacity in patients receiving longterm thyrotropin suppressive therapy with levothyroxine. J Clin Endocrinol Metab 81:4224-4228.
53. Portella RB, Silva JL,Wagman MB, Oliveira FP, Buescu A, Vaisman M 2006 Exercise performance in young and middle-aged female patients with subclinical hyperthyroidism. Thyroid 16:731-735.
54. Mercuro G, Panzuto MG, Bina A, Leo M, Cabula R, Petrini L, Pigliaru F, Mariotti S 2000 Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab 85:159-164.
55. Hoftijzer HC, Heemstra KA, Corssmit EP, van der Klaauw AA, Romijn JA, Smit JW 2008 Quality of life in cured patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 93:200-203.
56. Tan LG, Nan L, Thumboo J, Sundram F, Tan LK 2007 Health-related quality of life in thyroid cancer survivors. Laryngoscope 117:507-510.
57. Biondi B, Fazio S, Carella C, Amato G, Cittadini A, Lupoli G, Saccà L, Bellastella A, Lombardi G 1993 Cardiac effects of long-term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 77:334-338.
58. Shapiro LE, Sievert R, Ong L, Ocampo EL, Chance RA, Lee M, Nanna M, Ferrick K, Surks MI 1997 Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine. J Clin Endocrinol Metab 82:2592-2595.
59. Ching GW, Franklyn JA, Stallard TJ, Daykin J, Sheppard MC Gammage MD 1996 Cardiac hypertrophy as a result of long-term thyroxine therapy and thyrotoxicosis. Heart 75:363-368.
60. Botella-Carretero JI, Gomez-Bueno M, Barrios V, Caballero C, García-Robles R, Sancho J, Escobar-Morreale HF 2004 Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma. Endocr-Relat Cancer 11:345-356.
61. Gullu S, Altuntas F, Dincer I, Erol C, Kamel N 2004 Effects of TSH-suppressive therapy on cardiac morphology and function: beneficial effects of the addition of betablockade on diastolic dysfunction. Eur J Endocrinol 150: 655-661.
62. Smit JW, Eustatia-Rutten CF, Corssmit EP, Pereira AM, Frölich M, Bleeker GB, Holman ER, van der Wall EE, Romijn JA, Bax JJ 2005 Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study. J Clin Endocrinol Metab 90:6041-6047.
63. Fazio S, Biondi B, Carella C, Sabatini D, Cittadini A, Panza N, Lombardi G, Saccà L 1995 Diastolic dysfunction in patients on thyroid-stimulating- hormone suppressive therapy with levothyroxine: beneficial effect of ß blockade. J Clin Endocrinol Metab 80:2222-2226.
64. Shargorodsky M, Serov S, Gavish D, Leibovitz E, Harpaz D, Zimlichman R 2006 Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma. Thyroid 16:381-386.
65. Biondi B, Palmieri EA, Lombardi G, Fazio S 2002 Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med 137:904-914.
66. Haider AW, Larson MG, Benjamin EJ, Levy D 1998 Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 32:1454-1459.
67. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP 1990 Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 322:1561-1566.
68. Bonow RO, Udelson JE 1992 Left ventricular diastolic dysfunction as a cause of congestive heart failure. Mechanisms and management. Ann Intern Med 117:502-510.
69. Flynn RW, Bonellie SR, Jung RT, Macdonald TM, Morris AD, Leese GP 2010 Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab [Epub ahead of print]. (in press)
70. Samuels MH 1998 Subclinical thyroid disease in the elderly. Thyroid 8:803-813.
71. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D'Agostino RB 1994 Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 331: 1249-1252.
72. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, Tracy RP, Ladenson PW 2006 Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 295:1033-1041.
73. Ladenson PW 1993 Thyrotoxicosis and the heart: something old and something new. J Clin Endocrinol Metab 77:332-333.
74. Stewart S, Hart CL, Hole DJ, McMurray JJ 2002A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/ Paisley study. Am J Med 113:359-364.
75. Staffurth JS, Gibberd MC, Fui SN 1977 Arterial embolism in thyrotoxicosis with atrial fibrillation. Br Med J 10:688-690.
76. Presti CF, Hart RG 1989 Thyrotoxicosis, atrial fibrillation, and embolism, revisited. Am Heart J 117:976-977.
77. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D 1998 Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation 98:946-952.
78. Stroke Risk in Atrial Fibrillation Working Group 2007 Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 69:546-554.
79. Bauer DC, Rodondi N, Stone KL, Hillier TA 2007 Thyroid hormone use, hyperthyroidism and mortality in older women. Am J Med 120:343-349.
80. Haentjens P, Van Meerhaeghe A, Poppe K, Velkeniers B 2008 Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol 159:329-341.
81. Iervasi G, Molinaro S, Landi P, Taddei MC, Galli E, Mariani F, L'Abbate A, Pingitore A 2007 Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med 167:1526-1532.
82. Radacsi A, Kovacs G, Bernard W, Feldkamp J, Horster FA, Szabolcs I 2003 Mortality rate of chronically ill geriatric patients with subnormal serum thyrotropin concentration: a 2-yr follow-up study. Endocrine 21:133-136.
83. Chubb SA, DavisWA, Davis TM 2006 Subclinical hypothyroidism and mortality in women with type 2 diabetes. Clin Endocrinol 64:476-477.
84. Liewendahl K, Helenius T, Lamberg BA, Mähönen H, Wä gar G 1987 Free thyroxine, free triiodothyronine, and thyrotropin concentrations in hypothyroid and thyroid carcinoma patients receiving thyroxine therapy. Acta Endocrinol (Copenh) 116:418-424.
85. Jonklaas J, Davidson B, Bhagat S, Soldin SJ 2008 Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. JAMA 299:769-777.
86. Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP, Oppenheimer JH 1987 Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med 316:764-770.
87. Hughes JM, Gallagher DL, Olson JE 1989 Plasma free thyroxine concentrations in patients receiving levothyroxine for thyroid suppression. Surgery 106:951-955.
88. Taimela E, Koskinen P, Nuutila P, Nikkanen V, Saraste M, Taimela S, Irjala K 1995 Free thyroid hormones and a thirdgeneration TSH assay in the detection of hyperthyroidism during long-term thyroxine treatment in thyroid carcinoma patients. Scand J Clin Lab Invest 55:181-186.
89. Gammage MD, Parle JV, Holder RL, Roberts LM, Hobbs FD, Wilson S, Sheppard MC, Franklyn JA 2007 Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med 167:928-934.
90. Gussekloo J, van ExelE,de Craen AJ,Meinders AE, FrolichM, Westendorp RG 2004 Thyroid status, disability and cognitive function, and survival in old age. JAMA 292:2591-2599.
91. van den Beld AW, Visser TJ, Feelders RA, Grobbee DE, Lamberts SW 2005 Thyroid hormone concentrations, disease, physical function, and mortality in elderly men. J Clin Endocrinol Metab 90:6403-6409.
92. Vestergaard P, Rejnmark L, Weeke J, Mosekilde L 2000 Fracture risk in patients treated for hyperthyroidism. Thyroid 10:341-348.
93. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P 1998 Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med 338:712-718.
94. Ongphiphadhanakul B, Alex S, Braverman LE, Baran DT 1992 Excessive L-thyroxine therapy decreases femoral bone mineral densities in the male rat: effect of hypogonadism and calcitonin. J Bone Miner Res 7:1227-1231.
95. Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M 2003 TSH is a negative regulator of skeletal remodeling. Cell 115:151-162.
96. Bassett JH, O'Shea PJ, Sriskantharajah S, Rabier B, Boyde A, Howell PG, Weiss RE, Roux JP, Malaval L, Clement-Lacroix P, Samarut J, Chassande O, Williams GR 2007 Thyroid hormone excess rather than thyrotropin deficiency induces osteoporosis in hyperthyroidism. Mol Endocrinol 21:1095-1107.
97. Quan ML, Pasieka JL, Rorstad O 2002 Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature. J Surg Oncol 79:62-69.
98. Heemstra KA, Hamdy NA, Romijn JA, Smit JW 2006 The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Thyroid 16:583-591.
99. Kung AW, Yeung SS 1996 Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J Clin Endocrinol Metab 81:1232-1236.
100. Müller CG, Bayley TA, Harrison JE, Tsang R 1995 Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance Thyroid 5:81-87.
101. Guo CY, Weetman AP, Eastell R 1997 Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin Endocrinol 46:301-307.
102. Fujiyama K, Kiriyama T, Ito M, Kimura H, Ashizawa K, Tsuruta M, Nagayama Y, Villadolid MC, Yokoyama N, Nagataki S 1995 Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women. Thyroid 5:13-17.
103. Rachedi F, Rohmer V, Six P, Duquenne M, Wion Barbot N, Minebois A, Bigorgne JC, Audran M 1999 Prolonged suppressive L-thyroxine therapy. Longitudinal study of the effect of LT4 on bone mineral density and bone metabolism markers in 71 patients. Presse Med 28:323-329.
104. Jódar E, Begoña López M, García L, Rigopoulou D, Marti ́nez G, Hawkins F 1998 Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass. Osteoporos Int 8:311-316.
105. McDermott MT, Perloff JJ, Kidd GS 1995A longitudinal assessment of bone loss in women with levothyroxinesuppressed benign thyroid disease and thyroid cancer. Calcif Tissue Int 56:521-525.
106. Solomon BL, Wartofsky L, Burman KD 1993 Prevalence of fractures in postmenopausal women with thyroid disease. Thyroid 3:17-23.
107. Bauer DC, Ettinger B, Nevitt MC, Stone KL 2001 Risk for the study of osteoporotic fractures. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 134:561-568.
108. Tamer I, Sargin M, Sargin H, Seker M, Babalik E, Tekce M, Yayla A 2005 The evaluation of left ventricular hypertrophy in hypertensive patients with subclinical hyperthyroidism. Endocr J 52:421-425.
109. Dahl P, Danzi S, Klein I 2008 Thyrotoxic cardiac disease. Curr Heart Fail Rep 5:170-176.
110. Estes NA III, Halperin JL, Calkins H, Ezekowitz MD, Gitman P, Go AS, McNamara RL, Messer JV, Ritchie JL, Romeo SJ, Waldo AL, Wyse DG, Bonow RO, DeLong E, Goff DC Jr., Grady K, Green LA, Hiniker A, Linderbaum JA, Masoudi FA, Piñ a IL, Pressler S, Radford MJ, Rumsfeld JS; American College of Cardiology; American Heart Association Task Force on Performance Measures; Physician Consortium for Performance Improvement; ACC/ AHA/Physician Consortium 2008 Clinical performance measures for adults with non valvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement developed in collaboration with the Heart Rhythm Society. J Am Coll Cardiol 51:865-884.
111. Belluzzi F, Sernesi L, Preti P, Salinaro F, Fonte ML, Perlini S 2009 Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 53:24-29.
112. Radford MJ, Arnold JM, Bennett SJ, Cinquegrani MP, Cleland JG, Havranek EP, Heidenreich PA, Rutherford JD, Spertus JA, Stevenson LW, Goff DC, Grover FL, Malenka DJ, Peterson ED, Redberg RF; American College of Cardiology; American Heart Association Task Force on Clinical Data Standards; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Failure Society of America 2005 ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with chronic heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Data Standards. Circulation 112:1888-1916.
113. Kung AW, Yeung SS 1996 Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J Clin Endocrinol Metab 81:1232-1236.
114. Schneider DL, Barrett-Connor EL, Morton DL 1994 Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen. JAMA 271:1245-1249.
115. Rosen HN, Moses AC, Garber J, Ross DS, Lee SL, Ferguson L, Chen V, Lee K, Greenspan SL 1998 Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. J Clin Endocrinol Metab 83:2324-2330.
116. Panico A, Lupoli GA, Fonderico F, Marciello F, Martinelli A, Assante R, Lupoli G 2009 Osteoporosis and thyrotropinsuppressive therapy: reduced effectiveness of alendronate. Thyroid 19:437-442.
117. Lameloise N, Siegrist-Kaiser C, O'Connell M, Burger A 2001 Differences between the effects of thyroxine and tetraiodothyroacetic acid on TSH suppression and cardiac hypertrophy. Eur J Endocrinol 144:145-154.
118. Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M 1999 Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 340:1075-1079.